Bofanglutide Linked to Meaningful Reductions in HbA1c in Adults With T2DM

For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 receptor agonist, is associated with meaningful reductions in hemoglobin A1C (HbA1c) levels compared to semaglutide.